UniProt Q8WXR4 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic (1-326)high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 97.6% | 2.4% | 82.96 | 0.513 |
| 2 | Ceritinib | 94.4% | 5.6% | 95.44 | 0.618 |
| 3 | Osimertinib | 90.9% | 9.1% | 97.24 | 0.733 |
| 4 | Netarsudil | 86.1% | 13.9% | 93.22 | 0.676 |
| 5 | Gilteritinib | 84.0% | 16.0% | 88.97 | 0.506 |
| 6 | Defactinib | 81.4% | 18.6% | 92.68 | 0.450 |
| 7 | Bosutinib | 79.8% | 20.2% | 87.22 | 0.555 |
| 8 | Alectinib | 78.3% | 21.7% | 95.49 | 0.651 |
| 9 | Nintedanib | 63.4% | 36.6% | 90.23 | 0.608 |
| 10 | Ponatinib | 54.5% | 45.5% | 78.23 | 0.534 |
| 11 | Midostaurin | 52.5% | 47.5% | 78.64 | 0.500 |
| 12 | Lenvatinib | 46.2% | 53.8% | 97.74 | 0.726 |
| 13 | Pacritinib | 44.3% | 55.7% | 88.64 | 0.452 |
| 14 | Lazertinib | 36.8% | 63.2% | 97.47 | 0.674 |
| 15 | Abemaciclib | 35.4% | 64.6% | 91.48 | 0.563 |
| 16 | Sunitinib | 29.6% | 70.4% | 91.73 | 0.524 |
| 17 | Neratinib | 28.7% | 71.3% | 93.18 | 0.597 |
| 18 | Pirtobrutinib | 23.1% | 76.9% | 99.49 | 0.656 |
| 19 | Vemurafenib | 21.2% | 78.8% | 96.49 | 0.598 |
| 20 | Gedatolisib | 20.3% | 79.7% | 99.75 | 0.611 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.10
- Epithelial log2(TPM+1): 0.28
- Fold change: -0.18
- Status: No significant change
High-confidence drugs
- Osimertinib — inh 90.9% · KISS 41.09
- Ceritinib — inh 94.4% · KISS 40.44
- Brigatinib — inh 97.6% · KISS 29.33
Selectivity landscape vs inhibition on MYO3B
Each point is one of the 92 approved drugs; color = inhibition % on MYO3B.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…